Alto Neuroscience (ANRO) Operating Leases (2023 - 2026)

Alto Neuroscience has reported Operating Leases for 3 years, with the latest figure at $3.6 million in Q1 2026.

• Quarterly Operating Leases fell 19.41% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 million (down 19.41% YoY) and the FY2025 annual result came in at $3.8 million, down 15.35% from the prior year.
• Operating Leases eased to $3.6 million in Q1 2026 per ANRO's latest filing, from $3.8 million in the prior quarter.
• Over five years, Operating Leases peaked at $5.2 million in Q3 2024 and troughed at $3.6 million in Q1 2026.
• A 3-year average of $4.2 million and a median of $4.2 million in 2025 frame the typical range for Operating Leases.
• The widest YoY moves for Operating Leases: up 15.35% in 2025, down 23.73% in 2025.
• Over 3 years, Operating Leases stood at $4.5 million in 2024, then slipped by 15.35% to $3.8 million in 2025, then declined by 7.01% to $3.6 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $3.6 million, $3.8 million, and $4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.